Among patients with a HER2-amplified (HER2-positive/HER2+) tumor, targeted monoclonal antibodies binding and blocking this receptor of which trastuzumab is the most commonly administered proved to be very effective [1], resulting in a major increase in survival in this inherently aggressive breast cancer subtype [2]. This evidence concerns the gene ERBB2 and neoplasm.